International Journal of COPD (Feb 2020)
New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency
Abstract
Joanna Chorostowska-Wynimko,1 Miriam Barrecheguren,2 Ilaria Ferrarotti,3 Timm Greulich,4 Robert A Sandhaus,5 Michael Campos6 1Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland; 2Department of Pneumology, University Hospital Vall d’Hebron, Barcelona, Spain; 3Department of Internal Medicine and Therapeutics, Pneumology Unit IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy; 4Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Centre Giessen and Marburg, Philipps-University, Member of the German Centre for Lung Research (DZL), Marburg, Germany; 5Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA; 6Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Miami School of Medicine, Miami, FL, USACorrespondence: Joanna Chorostowska-WynimkoDepartment of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, ul. Płocka 26, 01-138, Warsaw, PolandTel +48 22 43 12 158Fax +48 22 43 12 358Email [email protected]: Alpha-1 antitrypsin deficiency (AATD) is a rare and underdiagnosed genetic predisposition for COPD and emphysema and other conditions, including liver disease. Although there have been improvements in terms of awareness of AATD and understanding of its treatment in recent years, current challenges center on optimizing detection and management of patients with AATD, and improving access to intravenous (IV) AAT therapy – the only available pharmacological intervention that can slow disease progression. However, as an orphan disease with geographically dispersed patients, international cooperation is essential to address these issues. To achieve this, new European initiatives in the form of the European Reference Network for Rare Lung Diseases (ERN-LUNG) and the European Alpha-1 Research Collaboration (EARCO) have been established. These organizations are striving to address the current challenges in AATD, and provide a new platform for future research efforts in AATD. The first objectives of ERN-LUNG are to establish a quality control program for European AATD laboratories and create a disease management program for AATD, following the success of such programs in the United States. The main purpose of EARCO is to create a pan-European registry, with the aim of understanding the natural history of the disease and supporting the development of new treatment modalities in AATD and access to AAT therapy. Going further, other patient-centric initiatives involve improving the convenience of intravenous AAT therapy infusions through extended-interval dosing and self-administration. The present review will discuss the implementation of these initiatives and their potential contribution to the optimization of patient care in AATD.Keywords: Alpha-1 antitrypsin deficiency, registries, testing, self-administration, alternative dosing
